12/03/2014 – Salix Pharmaceuticals Ltd.
Issued: 12/01/2014
Salix pharmaceuticals Ltd., SLXP:
1. Continued hourly and especially a daily close today (Mon., Dec. 1) above $101.80 (and worst-case, $101.65) place Salix Pharmaceuticals in a ‘Buy‘ position for continued advance and test/attempt at $105.20, then $107.00, or higher.
2. Partial long position exit should be taken at/near $103.60, then at/near $105.20. Final long position exit should be taken at/near $107.00.
3. Once long, a protective sell stop should be placed at $101.30. This stop will be moved higher as the market continues to confirm.
David Williams
Issued: 12/01/2014
Salix Pharmaceuticals Ltd., SLXP:
1. Today (Mon., Dec. 1) Salix Pharmaceuticals closed the session at $101.59, just slightly below the lower end of the $101.65 ‘Buy‘ position noted in today’s earlier update.
2. Therefore, tomorrow’s (Tues., Dec. 2) session remains important and may prompt a new long entry. Will update.
David Williams
Issued: 12/04/2014
Salix pharmaceuticals SLXP:
1. Although no official long trade entry occurred, Salix pharmaceuticals completed the forecast advance from $101.65 buying territory to the forecast $105.20 (or higher) upside target. Today’s session high has been $107.96, so far. Will message any further entry or indication in Salix pharmaceuticals.
David Williams
CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.